DK3484926T3 - Humaniseret antistof mod o-acetyleret gd2 gangliosid (oacgd2) - Google Patents

Humaniseret antistof mod o-acetyleret gd2 gangliosid (oacgd2) Download PDF

Info

Publication number
DK3484926T3
DK3484926T3 DK17748642.0T DK17748642T DK3484926T3 DK 3484926 T3 DK3484926 T3 DK 3484926T3 DK 17748642 T DK17748642 T DK 17748642T DK 3484926 T3 DK3484926 T3 DK 3484926T3
Authority
DK
Denmark
Prior art keywords
oacgd2
ganglioside
acetylated
humanized antibody
humanized
Prior art date
Application number
DK17748642.0T
Other languages
English (en)
Inventor
Brigitte Assouline
Mickaël Terme
Doussal Jean-Marc Le
Mylene Dorvillius
Original Assignee
Ogd2 Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogd2 Pharma filed Critical Ogd2 Pharma
Application granted granted Critical
Publication of DK3484926T3 publication Critical patent/DK3484926T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
DK17748642.0T 2016-07-15 2017-07-17 Humaniseret antistof mod o-acetyleret gd2 gangliosid (oacgd2) DK3484926T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16001564.0A EP3269739A1 (en) 2016-07-15 2016-07-15 Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)
PCT/EP2017/000855 WO2018010846A1 (en) 2016-07-15 2017-07-17 Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)

Publications (1)

Publication Number Publication Date
DK3484926T3 true DK3484926T3 (da) 2022-05-23

Family

ID=56497521

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17748642.0T DK3484926T3 (da) 2016-07-15 2017-07-17 Humaniseret antistof mod o-acetyleret gd2 gangliosid (oacgd2)

Country Status (8)

Country Link
US (2) US11440968B2 (da)
EP (3) EP3269739A1 (da)
JP (3) JP2019532016A (da)
CN (1) CN109843928B (da)
CA (1) CA3030760A1 (da)
DK (1) DK3484926T3 (da)
ES (1) ES2913415T3 (da)
WO (1) WO2018010846A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3269739A1 (en) * 2016-07-15 2018-01-17 OGD2 Pharma Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)
CN110551218B (zh) * 2019-09-17 2021-03-30 达石药业(广东)有限公司 一种gd2纳米抗体及其应用
BR112022009181A2 (pt) * 2019-11-25 2022-07-26 Univ Kyoto Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t
US20240228659A1 (en) * 2021-04-14 2024-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022219076A1 (en) * 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
JP2024002416A (ja) * 2022-06-24 2024-01-11 株式会社三洋物産 遊技機
JP2024009402A (ja) * 2022-07-11 2024-01-23 株式会社三洋物産 遊技機
JP2024009404A (ja) * 2022-07-11 2024-01-23 株式会社三洋物産 遊技機
JP2024009407A (ja) * 2022-07-11 2024-01-23 株式会社三洋物産 遊技機
JP7586146B2 (ja) * 2022-07-11 2024-11-19 株式会社三洋物産 遊技機
JP2024009403A (ja) * 2022-07-11 2024-01-23 株式会社三洋物産 遊技機
JP7601065B2 (ja) * 2022-07-11 2024-12-17 株式会社三洋物産 遊技機
JP7601064B2 (ja) * 2022-07-11 2024-12-17 株式会社三洋物産 遊技機
JP2024009405A (ja) * 2022-07-11 2024-01-23 株式会社三洋物産 遊技機
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
US9334330B2 (en) * 2006-10-10 2016-05-10 Universite De Nantes Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
KR101834026B1 (ko) * 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
JP6482525B2 (ja) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター 高親和性抗ｇｄ２抗体
RU2702428C2 (ru) * 2013-04-29 2019-10-08 Огд2 Фарма Использование о-ацетилированного gd2 ганглиозида в качестве мишени как новый терапевтический и диагностический подход при злокачественных новообразованиях, содержащих опухолевые стволовые клетки
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
CA2956482A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3269739A1 (en) * 2016-07-15 2018-01-17 OGD2 Pharma Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)
EP3329937A1 (en) * 2016-12-05 2018-06-06 OGD2 Pharma Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs

Also Published As

Publication number Publication date
EP3484926A1 (en) 2019-05-22
JP2022101585A (ja) 2022-07-06
JP2024075587A (ja) 2024-06-04
CN109843928B (zh) 2024-07-05
CA3030760A1 (en) 2018-01-18
EP3269739A1 (en) 2018-01-17
CN109843928A (zh) 2019-06-04
EP3484926B1 (en) 2022-02-16
JP2019532016A (ja) 2019-11-07
US20190233537A1 (en) 2019-08-01
WO2018010846A1 (en) 2018-01-18
JP7549621B2 (ja) 2024-09-11
US11440968B2 (en) 2022-09-13
ES2913415T3 (es) 2022-06-02
US20230148349A1 (en) 2023-05-11
EP4019551A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
DK3484926T3 (da) Humaniseret antistof mod o-acetyleret gd2 gangliosid (oacgd2)
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
KR20180085002A (ko) 인간화된 항-cll-1 항체
KR102355950B9 (ko) Tigit에 대한 항체
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3191517T3 (da) Krydsreaktive siglec-antistoffer
HUE047929T2 (hu) Kiméra antigén receptor
IL250043A0 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
IL256097A (en) Antibody epitope
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
IL258502A (en) Chimeric antigen receptors targeted to psca
KR102568808B9 (ko) 면역활성화 항원 결합 분자
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
DK3154583T3 (da) Humane monoklonale antistoffer mod gangliosid gd2
IL248402B (en) Humanized antibodies against ceacam1
DK3166973T3 (da) Immunstimulerende monoklonale antistoffer mod human interleukin-2
HUE061076T2 (hu) Humanizált anti-C1s ellenanyagok alkalmazási eljárások
EP3326560A4 (en) ULTRASOUND PROBE
HUE046181T2 (hu) Javított ellenanyagok IL-6 ellen
BR112017005006A2 (pt) inversão sísmica restringida por medições em tempo real
LT3390450T (lt) Antii-cd28 humanizuoti antikūnai, paruošti vartoti žmonėms
DK3256154T3 (da) Farmaceutisk formulering omfattende antistof
EP3567053A4 (en) ANTI-CLAUDINE-2 MONOCLONAL ANTIBODY
EP3559030C0 (en) ANTI-IL-5 ANTIBODIES
IL257368A (en) Antibody